Literature DB >> 15579744

A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.

Karen L Herbst1, Andrea D Coviello, Stephanie Page, John K Amory, Bradley D Anawalt, William J Bremner.   

Abstract

Acyline is a novel GnRH antagonist that reliably inhibits gonadotropins and testosterone (T) levels in men for 48 h after a single dose up to 75 microg/kg. In this study we examined gonadotropin and T levels in 28 healthy young men administered acyline as single doses of 150 or 300 microg/kg or serial injections of 75 microg/kg. A single 300 microg/kg dose of acyline suppressed gonadotropins and T to castrate levels for 15 d (baseline, 21.1 +/- 3.1; nadir, 1.95 +/- 0.4 nmol/liter; mean +/- sem; P < 0.05). Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d). Injections of 75 microg/kg acyline every 2 d for five doses suppressed gonadotropins for more than 20 d (nadir T, 1.06 +/- 0.17 nmol/liter; P < 0.05 compared with baseline). Adverse events were mild and included erythema and pruritus at the injection site. Acyline, therefore, is one of the most potent peptide GnRH antagonists studied to date with minimal adverse events. A twice monthly injection of acyline could be used as a potent suppressor of the GnRH axis to advance the development of a hormonal male contraceptive or for treatment of hormonally dependent disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579744     DOI: 10.1210/jc.2003-032123

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men.

Authors:  M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; B Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Gonadotropins regulate rat testicular tight junctions in vivo.

Authors:  Mark J McCabe; Gerard A Tarulli; Sarah J Meachem; David M Robertson; Peter M Smooker; Peter G Stanton
Journal:  Endocrinology       Date:  2010-03-31       Impact factor: 4.736

3.  Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.

Authors:  Katya B Rubinow; Tomas Vaisar; Jing H Chao; Jay W Heinecke; Stephanie T Page
Journal:  J Clin Lipidol       Date:  2018-04-30       Impact factor: 4.766

4.  Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men.

Authors:  Katya B Rubinow; Chongren Tang; Andrew N Hoofnagle; Christin N Snyder; John K Amory; Jay W Heinecke; Stephanie T Page
Journal:  Steroids       Date:  2012-01-15       Impact factor: 2.668

5.  Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency.

Authors:  M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; C N Snyder; B T Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

6.  Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men.

Authors:  Jing Chao; Katya B Rubinow; Mario Kratz; John K Amory; Alvin M Matsumoto; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2016-08-02       Impact factor: 5.958

7.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

8.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

9.  Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial.

Authors:  Mara Y Roth; Kat Lin; Katrine Bay; John K Amory; Bradley D Anawalt; Alvin M Matsumoto; Brett T Marck; William J Bremner; Stephanie T Page
Journal:  Fertil Steril       Date:  2012-10-03       Impact factor: 7.329

10.  Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole.

Authors:  M Y Roth; J J S Nya-Ngatchou; K Lin; S T Page; B D Anawalt; A M Matsumoto; B T Marck; W J Bremner; J K Amory
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.